Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,517.20
(
0.80%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
105.21
(
-0.52%
)
Bitcoin
81,196.80
(
0.88%
)
News Focus
News Focus
Post# of 257553
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 228398

Wednesday, 06/03/2020 1:51:56 PM

Wednesday, June 03, 2020 1:51:56 PM

Post# of 257553
ASMB claims that an acceptable endpoint for FDA approval of a new HBV drug is absence of HBV DNA six months* after terminating treatment, without regard to HBsAg levels.

*ASMB acknowledges that the duration of the off-treatment period is not set in stone and could be longer than six months.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today